Key result
Rivaroxaban successfully treats unprovoked PE in a case of antithrombin deficiency without early complications.
Why the study?
Does rivaroxaban provide an appropriate treatment for unprovoked pulmonary embolism in a patient with antithrombin deficiency?
Case Report (n=1)
Does rivaroxaban provide an appropriate treatment for unprovoked pulmonary embolism in a patient with antithrombin deficiency?
Rivaroxaban may serve as an appropriate and convenient treatment option for unprovoked pulmonary embolism in patients with antithrombin deficiency.
May inform rare antithrombin deficiency cases with PE; leaves open need for controlled trials before practice change.
A 24-year-old woman with antithrombin (AT) deficiency presented with right-sided pleuritic chest pain of five days duration with diagnosis of pulmonary embolism (PE) made at an outside hospital. After discussion of treatment options with the patient, her treatment was changed to rivaroxaban protocol. The case illustrates an appropriate treatment plan for patients with AT deficiency presenting with unprovoked PE, especially when prioritizing ease of use.
No takes yet. Share an insight, caveat, or question.
Gryn et al. (2020) conducted a case report in Unprovoked Pulmonary Embolism with Antithrombin Deficiency (n=1). Rivaroxaban was evaluated on Clinical outcome and complications. Rivaroxaban was successfully used to treat an unprovoked pulmonary embolism in a 24-year-old woman with antithrombin deficiency, with no complications reported at three months follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: